TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Shin Nippon Biomedical Laboratories, Ltd. ( (JP:2395) ).
Shin Nippon Biomedical Laboratories reported a significant increase in revenue for the three months ending June 30, 2025, with a 16.7% rise compared to the previous year. Despite the revenue growth, the company faced a consolidated operating loss, although ordinary profit and profit attributable to owners showed substantial improvements. The financial results indicate a complex financial situation, with implications for stakeholders regarding the company’s operational efficiency and market strategy.
The most recent analyst rating on (JP:2395) stock is a Hold with a Yen1460.00 price target. To see the full list of analyst forecasts on Shin Nippon Biomedical Laboratories, Ltd. stock, see the JP:2395 Stock Forecast page.
More about Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd. operates in the biomedical industry, focusing on providing comprehensive research and development services. The company is listed on the Prime Market of the Tokyo Stock Exchange and is known for its contributions to the pharmaceutical and biotechnology sectors.
Average Trading Volume: 289,804
Technical Sentiment Signal: Hold
Current Market Cap: Yen58.16B
Learn more about 2395 stock on TipRanks’ Stock Analysis page.